capecitabine with oxaliplatin

PreclinicalSmall molecule

capecitabine with oxaliplatin is one of 34 small molecule programs targeting Locally Advanced. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally AdvancedUnknown status

Locally AdvancedPreclinical

Unknown status

Competition

Competitive Landscape

39 competitors in Locally Advanced

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Approved

12 2

Eloxatin

Teva

Approved

6 3

Camptosar

Pfizer

Approved

2 4

Padcev

Pfizer

Approved

1 5

Adrucil

EElorac, Inc.

Approved

5 6

Taxol

Teva

Phase 3

7 7

Imfinzi

AstraZeneca

Phase 3

4 8

Truqap

AstraZeneca

Phase 3

1 9

Paraplatin

AAvyxa

Phase 3

8 10

Tuoyi

CCoherus Oncology, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Locally Advanced1 trial

Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.

Unknown status·PPeking Union Medical College Hospital·N/A·NCT03042000·1,200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for capecitabine with oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — capecitabine with oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for capecitabine with oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeking Union Medical College Hospital

capecitabine with oxaliplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Locally Advanced1 trial

References

Drug Info

Quick Facts

Related News